17
Participants
Start Date
October 2, 2020
Primary Completion Date
January 24, 2023
Study Completion Date
January 24, 2023
Blinatumomab
Blinatumomab will be administered as a continuous intravenous infusion (cIV).
AMG 404
AMG 404 will be administered as an intravenous infusion (IV).
Dexamethasone Premedication
Dexamethasone will be administered orally or intravenously prior to blinatumomab treatment, as needed.
The Royal Melbourne Hospital, Parkville
Ordensklinikum Linz Elisabethinen, Linz
Royal Adelaide Hospital, Adelaide
Icahn School of Medicine at Mount Sinai, New York
Universitätsklinikum Schleswig-Holstein, Kiel
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia
Azienda Ospedaliera Universitaria di Bologna Policlinico S Orsola Malpighi, Bologna
Cleveland Clinic Taussig Cancer Center, Cleveland
Klinikum und Fachbereich Medizin Johann Wolfgang Goethe-Universität Frankfurt am Main, Frankfurt am Main
University of Chicago, Chicago
Centre Hospitalier Lyon Sud, Pierre-Bénite
Hôpital Saint Louis, Paris
University of Texas MD Anderson Cancer Center, Houston
City of Hope National Medical Center, Duarte
Universitaetsklinikum Regensburg, Regensburg
Universitair Medisch Centrum Groningen, Groningen
Hospital Universitari Germans Trias i Pujol, Badalona
Hospital Clinic i Provincial de Barcelona, Barcelona
University College London, London
Lead Sponsor
Amgen
INDUSTRY